Skip to main content
Top
Published in: Cancer Causes & Control 1/2009

01-02-2009 | Original Paper

Estimating key parameters in FOBT screening for colorectal cancer

Authors: Dongfeng Wu, Diane Erwin, Gary L. Rosner

Published in: Cancer Causes & Control | Issue 1/2009

Login to get access

Abstract

Objectives

The association between screening sensitivity, transition probability, and individual’s age in FOBT for colorectal cancer are explored, for both males and females.

Methods

We apply the statistical method developed by Wu et al. [1] using the Minnesota colorectal cancer study group data, to make Bayesian inference for the age-dependent screening test sensitivity, the age-dependent transition probability from disease-free to preclinical state, and the sojourn time distribution, for both male and female participants in a periodic screening program. This gives us more information on the effectiveness of the fecal occult blood test in colorectal cancer detection.

Results

The sensitivity appears to increase with age for both genders. However, the posterior mean sensitivity is not monotonic with age for males; it has a peak around age 74. The standard errors of the sensitivity are not monotone either; there is a minimum at age 69 for males and at age 78 for females. The age-dependent transition probability is not a monotone function of age; it has a single maximum at age 72 for males and a single maximum at age 75 for females. The age dependency seems more dramatic for females than for males. The posterior mean sojourn time is 4.08 years for males and 2.41 years for females, with a posterior median of 1.66 years for males and 1.88 years for females. The 95% highest posterior density (HPD) interval is (0.97, 20.28) for males and (1.15, 5.96) for females, which are very large ranges, especially for males. The reason might be that there were fewer men than women in the annual screening program.

Conclusion

Reliable estimates of age-dependent sensitivity and transition probability are of great value to policy-makers regarding the initial age for colorectal cancer screening exams. We found that the mean sojourn time for males is much longer than that for females, which may imply that FOBT screening for colorectal cancer may be more effective for males than for females.
Literature
4.
go back to reference Anderson WF, Guyton KA, Hiatt RA et al (2002) Colorectal cancer screening for person at average risk. J Natl Cancer Inst 94:1126–1133PubMed Anderson WF, Guyton KA, Hiatt RA et al (2002) Colorectal cancer screening for person at average risk. J Natl Cancer Inst 94:1126–1133PubMed
5.
7.
go back to reference Prevost TC, Launoy G, Duffy SW et al (1998) Estimating sensitivity and sojourn time in screening for colorectal cancer. Am J Epidemiol 148(6):609–619PubMed Prevost TC, Launoy G, Duffy SW et al (1998) Estimating sensitivity and sojourn time in screening for colorectal cancer. Am J Epidemiol 148(6):609–619PubMed
8.
go back to reference Walter SD, Day NE (1983) Estimation of the duration of a preclinical disease state using screening data. Am J Epidemiol 118:856–886 Walter SD, Day NE (1983) Estimation of the duration of a preclinical disease state using screening data. Am J Epidemiol 118:856–886
Metadata
Title
Estimating key parameters in FOBT screening for colorectal cancer
Authors
Dongfeng Wu
Diane Erwin
Gary L. Rosner
Publication date
01-02-2009
Publisher
Springer Netherlands
Published in
Cancer Causes & Control / Issue 1/2009
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-008-9215-9

Other articles of this Issue 1/2009

Cancer Causes & Control 1/2009 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine